The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| BHC | -19.09% | -59.94% | -16.71% | +1,871% |
| S&P | +17.35% | +108.64% | +15.84% | +1,408% |
Bausch Health Cos., Inc. engages in the development, manufacture and market of a range of branded, generic and branded generic pharmaceuticals, medical devices and over-the-counter products. It operates through the following segments: Salix, International, Solta Medical, Diversified Products, and Bausch + Lomb. The Salix segment consists of sales in the U.S. of GI products. Sales of the Xifaxan product line. The International segment comprises of sales, with the exception of sales of Bausch + Lomb products and Solta aesthetic medical devices, outside the U.S and Puerto Rico of branded pharmaceutical products, branded generic pharmaceutical and OTC products. The Solta Medical segment refer to global sales of Solta Medical aesthetic medical devices. The Diversified Products segment covers sales in the U.S. of pharmaceutical products in the areas of neurology and certain other therapeutic classes, generic products, ortho dermatologics, and dentistry products. The Bausch + Lomb segment are global sales of Bausch + Lomb vision care, surgical and ophthalmic pharmaceuticals products. The company was founded on March 29, 1994 and is headquartered in Laval, Canada.
The Motley Fool analyzed 16 billionaire-led hedge funds to get an idea of their healthcare sector investment strategies.
| Q3 2025 | YOY Change | |
|---|---|---|
| Revenue | $2.68B | 6.8% |
| Gross Profit | $1.68B | 9.0% |
| Gross Margin | 62.59% | 1.2% |
| Market Cap | $397.29M | -20.4% |
| Market Cap / Employee | $0.02M | 0.0% |
| Employees | 20.7K | 2.1% |
| Net Income | $181.00M | 296.7% |
| EBITDA | $1.02B | 18.1% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2025 | YOY Change | |
|---|---|---|
| Net Cash | $1.34B | 78.7% |
| Accounts Receivable | $2.42B | 15.4% |
| Inventory | 1.6K | -3.4% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $20.46B | -2.8% |
| Short Term Debt | $579.00M | 27.8% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Return On Assets | 1.36% | 2.0% |
| Return On Invested Capital | -2.13% | 1.3% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | $315.99M | -4.6% |
| Operating Free Cash Flow | $407.72M | 1.3% |
| Metric | Q2 2025 | YoY Change | |||
|---|---|---|---|---|---|
| Price to Earnings | 25.41 | - | |||
| Price to Book | -0.42 | -0.31 | -0.35 | -0.52 | 22.47% |
| Price to Sales | 0.32 | 0.31 | 0.25 | 0.25 | -10.21% |
| Price to Tangible Book Value | -0.03 | -0.02 | -0.02 | -0.02 | -15.33% |
| Price to Free Cash Flow TTM | 2.90 | 2.42 | 2.00 | 2.34 | -17.16% |
| Enterprise Value to EBITDA | 27.54 | 41.15 | 31.01 | 22.86 | -19.40% |
| Free Cash Flow Yield | 34.5% | 41.4% | 49.9% | 42.7% | 20.71% |
| Total Debt | $21.84B | $21.51B | $21.74B | $21.04B | -2.16% |
BHC earnings call for the period ending October 2, 2021.
BHC earnings call for the period ending June 30, 2021.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
